bioMerieux (OTCMKTS:BMXMF) Given Consensus Rating of “Reduce” by Analysts

Posted by Patrick Bannon on Sep 13th, 2026

bioMerieux (OTCMKTS:BMXMF – Get Free Report) has been given a consensus recommendation of “Reduce” by the six brokerages that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating and four have issued a hold rating on the company.

Several brokerages have commented on BMXMF. Morgan Stanley reaffirmed an “underweight” rating on shares of bioMerieux in a research report on Friday. Zacks Research lowered shares of bioMerieux from a “hold” rating to a “strong sell” rating in a research note on Friday, July 31st. Piper Sandler started coverage on shares of bioMerieux in a report on Thursday, June 11th. They issued a “neutral” rating on the stock. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Finally, UBS Group lowered bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st.

View Our Latest Stock Report on bioMerieux

bioMerieux Price Performance

bioMerieux stock opened at $86.11 on Friday. bioMerieux has a fifty-two week low of $77.00 and a fifty-two week high of $138.15. The firm’s 50-day simple moving average is $82.33 and its 200 day simple moving average is $90.85. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.48 and a current ratio of 2.39.

bioMerieux Company Profile

(Get Free Report)

bioMérieux (OTCMKTS:BMXMF) is a France-based company specializing in in vitro diagnostics. It develops, manufactures and markets diagnostic systems used to detect infectious diseases, support antimicrobial treatment decisions and improve patient care in clinical settings.

The company’s product portfolio includes molecular biology tests, microbiology systems, immunoassays and syndromic testing solutions. Its clinical diagnostic products are used by hospitals, laboratories and other healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetic industries through solutions for detecting microorganisms and monitoring contamination.

Established in 1963, bioMérieux traces its roots to the Mérieux family’s longstanding involvement in medical research and diagnostics in France.